ERBB3 and colorectal carcinoma: Despite this, proteins of HER3 and PR were identified to be negative prognostic biomarkers in both STAD and CRC patients (Figure 6B,C), which may warrant further studies since they offer significant potential as candidate biomarkers for precision medicine approaches of GI cancers.